Liangan Chen

Dr. Liangan Chen


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2023 in Translational Lung Cancer Research
Verified
Journal Article
Open access
PDF file
CZChengzhi Zhou
Chengzhi Zhou
YQYinyin Qin
Yinyin Qin
WZWei Zhao
Wei Zhao
ZLZhenyu Liang
Zhenyu Liang
MLMin Li
Min Li
RCRongchang Chen
Rongchang Chen
Background: Lung cancer combined by chronic obstructive pulmonary disease (LC-COPD) is a common comorbidity and their interaction with each other poses significant clinical challenges. However, there is a lack of well-established consensus on the diagnosis and treatment of LC-COPD. Methods: A panel of experts, comprising specialists in oncology, respiratory medicine, radiology, interventional medicine, and thoracic surgery, was convened. The panel was presented with a comprehensive review of the current evidence pertaining to LC-COPD. After thorough discussions, the panel reached a consensus on 17 recommendations with over 70% agreement in voting to enhance the management of LC-COPD and optimize the care of these patients. Results: The 17 statements focused on pathogenic mechanisms (n=2), general strategies (n=4), and clinical application in COPD (n=2) and lung cancer (n=9) were developed and modified. These statements provide guidance on early screening and treatment selection of LC-COPD, the interplay of lung cancer and COPD on treatment, and considerations during treatment. This consensus also emphasizes patient-centered and personalized treatment in the management of LC-COPD. Conclusions: The consensus highlights the need for concurrent treatment for both lung cancer and COPD in LC-COPD patients, while being mindful of the mutual influence of the two conditions on treatment and monitoring for adverse reactions.

22 May 2014 in Oncology Letters
Verified
Journal Article
Open access
PDF file
YLYun Li
Yun Li
WZWeiguo Zhao
Weiguo Zhao
PBPengtao Bao
Pengtao Bao
CLChunsun Li
Chunsun Li
XMXiu Qing Ma
Xiu Qing Ma
LCLiangan Chen
Liangan Chen
The aim of the present study was to investigate the potential role of microRNA (miRNA or miR) in invasion and metastasis of non‑small cell lung cancer (NSCLC). miRNA‑microarray analysis was used to detect the differentially expressed miRNAs between various metastatic levels of NSCLC cells. The microarray results were verified by quantitative polymerase chain reaction. The most clearly altered miRNA, miR‑339‑5p, was transfected into NSCLC cells and cell migration and invasion were investigated. The expression of miR‑339‑5p was 3.4662‑fold higher in the lower metastatic NSCLC cells. miR‑339‑5p significantly decreased tumor‑cell migration and the invasion capacity in vitro. In conclusion, miR‑339‑5p is important in NSCLC invasion and metastasis, indicating that miR‑339‑5p could be further evaluated as a biomarker for predicting the survival time of patients with NSCLC.

23 January 2013 in Thoracic Cancer
Verified
Journal Article
Open access
PDF file
QTQing Tian
Qing Tian
LCLiangan Chen
Liangan Chen
RWRen‐Tao Wang
Ren‐Tao Wang
ZYZhen Yang
Zhen Yang
YAYang An
Yang An
Although the sensitivity can reach 99%, endobronchial ultrasound‐guided transbronchial needle aspiration (EBUS‐TBNA) has a significantly high false negative rate for diagnosis and staging of thoracic malignancy. We performed this retrospective study to investigate the causes of false negative results and to improve the efficacy and accuracy of EBUS‐TBNA. We reviewed all patients suspected of intrapulmonary or mediastinal malignancy who undertook EBUS‐TBNA between July 2009 and August 2012 in Chinese PLA general hospital. We retrieved the pathological results of EBUS‐TBNA and video‐assisted thoracic surgery (VATS) and follow‐up data. The sensitivity, specificity, positive predictive value and negative predictive value were calculated. 185 patients were included in this study. Diagnosis of malignancy was established on 172 patients by EBUS‐TBNA, and 8 patients with negative EBUS‐TBNA result gained their final diagnosis of malignancy via VATS. The sensitivity, specificity, negative predictive value and accuracy for diagnosis of malignancy for EBUS‐TBNA were 96%, 100%, 33% and 96% respectively. Inadequacy of the EBUS‐TBNA specimens, internal necrosis in the lymph nodes and rare cancer types contributed to the false negative EBUS‐TBNA results. VATS is obligatory to explain the negative results of EBUS‐TBNA in patients suspected of malignancy.

17 June 2010 in Journal of Medical Case Reports
Verified
Journal Article
Open access
PDF file
WZWeihua Zhang
Weihua Zhang
YHYe Hu
Ye Hu
LCLiangan Chen
Liangan Chen
JGJie Gao
Jie Gao
LXLixin Xie
Lixin Xie
Introduction: Pneumothorax as the first symptom of pleural aspergillosis is rare. Case presentation: A 31-year-old asthmatic Chinese man presented with recurrent spontaneous pneumothorax and underwent lobectomy due to persistent air leakage. Aspergillus was detected histopathologically in the visceral pleural cavity. He was treated with itraconazole at 200 mg a day, and nine months later he had no recurrent pneumothorax or aspergillus infection. Conclusion: Recurrent pneumothorax may be a rare manifestation of aspergillus infection. Aspergillus species infection should be considered in the differential diagnosis of recurrent pneumothorax patients, particularly those with chronic lung disease.

28 December 2012 in Inflammation
Verified
Journal Article
Closed access
PDF file
SXShufeng Xu
Shufeng Xu
PWPing Wang
Ping Wang
KWKun Wei
Kun Wei
FLFengsui Liu
Fengsui Liu
ZLZhixin Liang
Zhixin Liang
LCLiangan Chen
Liangan Chen

1 March 2016 in Molecular Medicine Reports
Verified
Journal Article
Open access
PDF file
LCLu Cao
Lu Cao
CLChun‑Sun Li
Chun‑Sun Li
YCYan Chang
Yan Chang
ZLZhi‑Xin Liang
Zhi‑Xin Liang
LCLiangan Chen
Liangan Chen
Acute lung injury (ALI)/ARDS is a critical clinical syndrome with high mortality, and the effective therapeutic methods for the treatment remain limited. Previous studies have indicated that liquid ventilation with perfluorocarbon (PFC) may be advantageous over conventional mechanical ventilation in the treatment of ALI/ARDS. Additionally, PFC inhibits the inflammatory response caused by ALI/ARDS. However, the anti-inflammatory mechanism remains to be completely elucidated. In the present study, the aim was to determine the anti‑inflammatory mechanism of PFC and the association with microRNA (miR). PFC was used to modulate LPS‑induced A549 cells, with the cells divided into four groups: Untreated control group; LPS group, treated with 10 µg/ml LPS; LPS+PFC group, treated with 10 µg/ml LPS and PFC; and PFC group, treated with PFC alone. The intercellular adhesion molecule‑1 (ICAM‑1) mRNA and protein expression levels of each group were detected by reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) and western blotting, respectively. A549 cells were transfected with miR‑17‑3p mimics, miR‑17‑3p inhibitors or negative controls to observe the alterations in the anti‑inflammatory effects of PFC. A dual luciferase reporter gene assay was used to determine whether ICAM‑1 is a target gene of miR‑17‑3p. PFC was observed to attenuate the mRNA and protein expression levels of ICAM‑1 in LPS‑induced A549 cells, with no significant effect on the untreated A549 cells. miR‑17‑3p was demonstrated to be regulated by PFC. Transfection with miR‑17‑3p mimics enhanced the anti‑inflammatory effects of PFC, whereas the miR‑17‑3p inhibitor weakened the anti‑inflammatory effects of PFC at early time points. To conclude, the current study indicates that ICAM‑1 was a target gene of miR‑17‑3p, and PFC has anti‑inflammatory effects. Additionally, the present study is the first report, to the best of our knowledge, that PFC is able to attenuate ICAM-1 expression in LPS-induced A549 cells by increasing miR-17-3p expression.